Aptus Health will continue to operate as an independent subsidiary of WebMD, as the companies build on and integrate products, platforms, and services. "Univadis strengthens our commitment to deliver best-in-class content and tools to millions of physicians worldwide," said Jeremy Schneider, Senior Vice President and Group General Manager, WebMD Global. "With Univadis, we deepen our connection to local markets, extend our reach to HCP audiences and increase our value to customers."īased in Reading, MA, Aptus Health is wholly owned by Merck, known as MSD outside the United States and Canada. The addition of Aptus Health's flagship brand Univadis to the Medscape franchise will build on Medscape's unrivaled reach as the leading global source of clinical news, health information, education and point-of-care tools for health care professionals worldwide. "Together, we can leverage our combined strengths to extend our reach and engagement to health care professionals, patients and consumers."
APTUS FASILITATOR PROFESSIONAL
"Aptus Health is highly complementary to WebMD's existing professional and consumer brands, making them an excellent addition to our platforms," said Bob Brisco, WebMD CEO. The acquisition will combine the core competencies and scale of Aptus Health with that of WebMD and Medscape, the flagship consumer and health care professional brands in the WebMD network. In addition, the transaction includes Aptus Health's EngagedMedia, which supports patient engagement and adherence via an integrated mobile messaging platform and Tomorrow Networks, which offers data-driven, location-based mobile advertising and marketing solutions driven by consumer behavior. The acquisition includes Aptus Health's core brand Univadis, a global information and education platform delivering medical news, conference and research updates and thought-leader education to 4 million HCPs in 91 countries. 30, 2019 /PRNewswire/ - WebMD Health Corp., an Internet Brands company and the leader in health information services for consumers, physicians, and other healthcare professionals (HCPs), today announced that it has entered into an agreement to acquire Aptus Health. This activity can minimize the effects of what would be toxic, allowing for healthy growth once again.NEW YORK, Sept. In a soil-container environment, Fasilitor through the action of silicic acid will work to regulate how much of a mineral is let into the plant.
During bloom transition, use at 1.2ml per gallon or 6ml per 5 gallon to reduce plant stretching.
Use for the entire vegetative and bloom cycles at the rate of 0.6ml per gallon or 3ml per 5 gallons.Reduces transpiration (loss of moisture from the leaves) by forming thick cell walls which are made primarily of silica and calcium.Increases resistance against salinity (nutrient salt buildup) by limiting uptake of excess minerals present in the planting medium.Reduces internodal spacing by adjusting mineral translocation to new limbs.Stronger cell structures and epidermis layer creating thicker tissue (increases dry yield).Improves uptake, absorption and utilisation of nutrients.Resistance against biotic stress (living: pests and pathogens).Resistance against abiotic (environmental: temperature, wind, drought).The patented and stabilized concentration of monomer silicic acid particles allows for fast response against abiotic and biotic stress factors (environmental and pests), shorter internodal spacing, incredible bio-availability, and increased yields all while utilizing natural mechanisms within the plant to gain these benefits. Fasilitor's patented formula works by increasing vascular pressure within the plant to heighten mineral translocation throughout its entire structure resulting in more complete, robust, and quality tissue formation. While it is a silica-based solution, it is unlike any other silica product on the market. FASILITOR Nutrition Manager and Plant StrengthenerĪbout Fasilitor As the flagship of the Aptus product lineup, Fasilitor is extremely concentrated, pure, and fast-acting.
0 kommentar(er)
